814 related articles for article (PubMed ID: 26205347)
21. Role of ATM in the formation of the replication compartment during lytic replication of Epstein-Barr virus in nasopharyngeal epithelial cells.
Hau PM; Deng W; Jia L; Yang J; Tsurumi T; Chiang AK; Huen MS; Tsao SW
J Virol; 2015 Jan; 89(1):652-68. PubMed ID: 25355892
[TBL] [Abstract][Full Text] [Related]
22. Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle.
Daigle D; Gradoville L; Tuck D; Schulz V; Wang'ondu R; Ye J; Gorres K; Miller G
J Virol; 2011 Jun; 85(11):5628-43. PubMed ID: 21411522
[TBL] [Abstract][Full Text] [Related]
23. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
24. A Screen for Epstein-Barr Virus Proteins That Inhibit the DNA Damage Response Reveals a Novel Histone Binding Protein.
Ho TH; Sitz J; Shen Q; Leblanc-Lacroix A; Campos EI; Borozan I; Marcon E; Greenblatt J; Fradet-Turcotte A; Jin DY; Frappier L
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743367
[TBL] [Abstract][Full Text] [Related]
25. Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
Novalić Z; Verkuijlen SAWM; Verlaan M; Eersels JLH; de Greeuw I; Molthoff CFM; Middeldorp JM; Greijer AE
J Med Virol; 2017 Dec; 89(12):2207-2216. PubMed ID: 28853217
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.
Kim SJ; Kim JH; Ki CS; Ko YH; Kim JS; Kim WS
Ann Oncol; 2016 Mar; 27(3):508-13. PubMed ID: 26658891
[TBL] [Abstract][Full Text] [Related]
27. Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
Hsu CL; Kuo YC; Huang Y; Huang YC; Lui KW; Chang KP; Lin TL; Fan HC; Lin AC; Hsieh CH; Lee LY; Wang HM; Li HP; Chang YS
Oncotarget; 2015 Oct; 6(31):31323-34. PubMed ID: 26416517
[TBL] [Abstract][Full Text] [Related]
28. The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.
Conforti F; Davies ER; Calderwood CJ; Thatcher TH; Jones MG; Smart DE; Mahajan S; Alzetani A; Havelock T; Maher TM; Molyneaux PL; Thorley AJ; Tetley TD; Warner JA; Packham G; Ganesan A; Skipp PJ; Marshall BJ; Richeldi L; Sime PJ; O'Reilly KMA; Davies DE
Oncotarget; 2017 Jul; 8(30):48737-48754. PubMed ID: 28467787
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
Li LH; Zhang PR; Cai PY; Li ZC
Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
[TBL] [Abstract][Full Text] [Related]
30. Rapamycin enhances lytic replication of Epstein-Barr virus in gastric carcinoma cells by increasing the transcriptional activities of immediate-early lytic promoters.
Wang M; Wu W; Zhang Y; Yao G; Gu B
Virus Res; 2018 Jan; 244():173-180. PubMed ID: 29169830
[TBL] [Abstract][Full Text] [Related]
31. Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells.
Imesch P; Fink D; Fedier A
Fertil Steril; 2010 Dec; 94(7):2838-42. PubMed ID: 20605144
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.
Ghosh SK; Perrine SP; Williams RM; Faller DV
Blood; 2012 Jan; 119(4):1008-17. PubMed ID: 22160379
[TBL] [Abstract][Full Text] [Related]
33. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
Feng WH; Hong G; Delecluse HJ; Kenney SC
J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
[TBL] [Abstract][Full Text] [Related]
34. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.
Countryman JK; Gradoville L; Miller G
J Virol; 2008 May; 82(10):4706-19. PubMed ID: 18337569
[TBL] [Abstract][Full Text] [Related]
35. Lytic induction and apoptosis of Epstein-Barr virus-associated gastric cancer cell line with epigenetic modifiers and ganciclovir.
Jung EJ; Lee YM; Lee BL; Chang MS; Kim WH
Cancer Lett; 2007 Mar; 247(1):77-83. PubMed ID: 16647201
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
[TBL] [Abstract][Full Text] [Related]
37. IL-10 knockdown with siRNA enhances the efficacy of Doxorubicin chemotherapy in EBV-positive tumors by inducing lytic cycle via PI3K/p38 MAPK/NF-kB pathway.
Gao L; Han H; Wang H; Cao L; Feng WH
Cancer Lett; 2019 Oct; 462():12-22. PubMed ID: 31352079
[TBL] [Abstract][Full Text] [Related]
38. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Karthik S; Sankar R; Varunkumar K; Ravikumar V
Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus (EBV) Rta-mediated EBV and Kaposi's sarcoma-associated herpesvirus lytic reactivations in 293 cells.
Chen YJ; Tsai WH; Chen YL; Ko YC; Chou SP; Chen JY; Lin SF
PLoS One; 2011 Mar; 6(3):e17809. PubMed ID: 21423768
[TBL] [Abstract][Full Text] [Related]
40. Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.
Gorres KL; Daigle D; Mohanram S; Miller G
J Virol; 2014 Jul; 88(14):8028-44. PubMed ID: 24807711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]